Large-cap Health Care company Takeda Pharmaceutical has logged a -1.3% change today on a trading volume of 1,403,759. The average volume for the stock is 3,424,733.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. Based in Tokyo, Japan the company has 47,455 full time employees and a market cap of $47,759,015,936. Takeda Pharmaceutical currently offers its equity investors a dividend that yields 1300.6% per year.
The company is now trading -12.36% away from its average analyst target price of $16.97 per share. The 4 analysts following the stock have set target prices ranging from $14.912758 to $18.942617, and on average give Takeda Pharmaceutical a rating of buy.
Over the last 52 weeks, TAK stock has risen 0.7%, which amounts to a -13.7% difference compared to the S&P 500. The stock's 52 week high is $15.56 whereas its 52 week low is $12.8 per share. Based on Takeda Pharmaceutical's average net margin growth of 15.4% over the last 6 years, its core business is on track for profitability and its strong stock performance may continue in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 4,581,551,000 | 108,143,000 | 2 | -33.33 |
| 2023 | 4,263,762,000 | 144,197,000 | 3 | -62.5 |
| 2022 | 4,027,478,000 | 317,038,000 | 8 | 33.33 |
| 2021 | 3,569,006,000 | 230,166,000 | 6 | -50.0 |
| 2020 | 3,197,812,000 | 376,171,000 | 12 | 1100.0 |
| 2019 | 3,291,188,000 | 44,290,000 | 1 |
